NYSE:ELN
E559465
NYSE:ELN was the stock ticker symbol for Elan Pharmaceuticals, an Irish biotechnology company known for developing treatments for neurological and autoimmune diseases.
Observed surface forms (1)
| Surface form | Occurrences |
|---|---|
| Elan Corporation plc | 0 |
Statements (47)
| Predicate | Object |
|---|---|
| instanceOf |
biotechnology company
ⓘ
public company ⓘ |
| acquiredBy | Perrigo Company plc NERFINISHED ⓘ |
| acquisitionDate | 2013 ⓘ |
| acquisitionValue | approximately $8.6 billion ⓘ |
| collaboratedWith |
Biogen Idec
NERFINISHED
ⓘ
Johnson & Johnson NERFINISHED ⓘ Wyeth NERFINISHED ⓘ |
| countryOfOrigin | Ireland ⓘ |
| currencyOfStock |
GBP
NERFINISHED
ⓘ
USD ⓘ |
| delistedFrom |
LSE
NERFINISHED
ⓘ
NYSE NERFINISHED ⓘ |
| developedFor |
Alzheimer's disease
ⓘ
Crohn's disease ⓘ multiple sclerosis ⓘ |
| focusesOn |
autoimmune diseases
ⓘ
neurological diseases ⓘ |
| formerTicker |
LSE:ELA
NERFINISHED
ⓘ
NYSE:ELN NERFINISHED ⓘ |
| foundedBy | Don Panoz NERFINISHED ⓘ |
| foundedIn | 1969 ⓘ |
| headquartersLocation | Dublin, Ireland NERFINISHED ⓘ |
| industry |
biotechnology
ⓘ
pharmaceuticals ⓘ |
| ISIN | IE0003072950 ⓘ |
| legalIssue | accounting and financial reporting investigations in early 2000s ⓘ |
| listedOn |
LSE
NERFINISHED
ⓘ
NYSE NERFINISHED ⓘ |
| notableEvent |
Tysabri safety concerns and temporary market withdrawal in 2005
ⓘ
reintroduction of Tysabri with risk management program ⓘ |
| notableMarket |
Europe
NERFINISHED
ⓘ
United States NERFINISHED ⓘ |
| notableProduct |
Antegren
NERFINISHED
ⓘ
Bapineuzumab NERFINISHED ⓘ Tysabri NERFINISHED ⓘ |
| primaryTherapeuticArea |
immunology
ⓘ
neurology ⓘ |
| reasonForDelisting | acquisition by Perrigo ⓘ |
| researchFocus |
biologic therapies
ⓘ
central nervous system disorders ⓘ monoclonal antibodies ⓘ |
| status | defunct as independent company ⓘ |
| stockExchange |
London Stock Exchange
NERFINISHED
ⓘ
New York Stock Exchange ⓘ |
| tradedAs |
LSE:ELA
NERFINISHED
ⓘ
NYSE:ELN ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.